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TP53 is frequently mutated in different types of neoplasms including leukemia and 
lymphomas. Mutations of TP53 have also been reported in mycosis fungoides (MF), 
the most common type of cutaneous lymphoma. However, little is known about the 
frequency, spectrum of mutations, and their prognostic significance in MF. In this study, 
we have optimized the protocol for Sanger sequencing of TP53 using DNA extracted 
from archival paraffin-embedded biopsies. Of 19 samples from patients with stage IIB 
MF or higher, 31% harbored mutations in TP53. Overall survival of the patients with 
mutated TP53 was significantly shorter than median survival in the age- and stage-
matched patients treated in our Institution. Distribution of mutations was heterogenous 
in TP53 exons; however, C > T transitions were common suggesting the causal role 
of ultraviolet radiation. We propose that TP53 mutation status would be useful for risk 
stratification of patients with advanced MF.
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inTrODUcTiOn
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and in 
most cases runs an indolent course. However, approximately 20% of patients would progress to a 
widespread disease with multiple skin tumors and extracutaneous involvement with dire outcome 
(1). Male gender, young age, and folliculotropic subtype are risk factors for progression, but their 
predictive value is low (1, 2). There are currently no robust biomarkers that predict the course of 
the disease.
The tumor suppressor gene TP53 is central in tumorigenesis and regarded as a master regulator of 
several signaling pathways involved in this process. TP53 is mutated in more than 50–70% of all solid 
tumors and in approximately 10–20% in hematological malignancies (3). While low-grade lymphoid 
neoplasms reveal low p53 mutation rates, lymphomas and leukemias (in particular chronic lymphatic 
leukemia) with an aggressive clinical course demonstrate higher frequencies (4–7). To this end, a 
strong correlation was found between p53 functional status and clinical outcomes in lymphoma, such 
as mortality or resistance to chemotherapy (8, 9). TP53 may be mutated in a proportion of patients 
with another type of CTCL, Sezary syndrome, but mutations are not predictive for the course of 
the disease (10). Less is known about TP53 gene status in MF. Previous studies suggested that p53 
overexpression and mutation is uncommon in early MF (11–13) but can be found in advanced stages 
indicating prognostic significance (14, 15). It has also been suggested that p53 mutations in MF 
are caused by ultraviolet radiation (11, 14, 16). Therefore, in this study we wished to elucidate the 
TaBle 1 | Patients with MF included in mutation analysis of TP53.
no. gender/
age (years)
clinical 
stage
Mutation status of TP53 Disease duration  
at highest stage
1 Male/67 T3N3M1B0 Mutated: exon 4: c.100C > T (p.P34S); exon 4: c.254C > T (p.P85L); exon 4: c.430C > T (p.Q144stop) 7 years, DOD
2 Female/91 T3N0M0B0 Mutated: exon 8: c.811G > A (p.E271K); exon 5 and 6 unable to amplify 1 year, DOD
3 Female/67 T4N3M0B2 No mutations 10 years, DOD
4 Male/72 T3N2M0B0 No mutations 2 years, AWD
5 Female/89 T3N0M0B0 No mutations 8 years, DOC
6 Female/56 T4N1M0B1 No mutations 5 years, DOD
7 Male/69 T3N3M1B0 No mutations: exon 5 and 6 unable to amplify 3 years, DOD
8 Male/76 T4N3M0B1a No mutations 3 years, DOD
9 Female/65 T3N1M0B0 No mutations 14 years, AWD
10 Male/83 T3N0M0B0 No mutations 11 years, AWD
11 Female/55 T3N0M0B0 No mutations 5 years, AWD
12 Male/75 T3N0M0B0 No mutations in exon 7, 10: exon 4, 5, 6, 8, and 9 unable to amplify 3 years, DOC
13 Male/64 T4N3M0B2 Mutated: exon 5: c.449C > T (p.T150I) 4 years, DOD
14 Female/74 T3N0M0B0 No mutations 6 years, AWD
15 Female/71 T3N0M0B0 No mutations 12 years, AWD
16 Female/63 T3N3M0B0 No mutations: exon 4, 5, and 6 unable to amplify 5 years, DOC
17 Male/76 T3N0M1B0 Mutated: exon 5: c. 502C > T (p.H168Y); exon 5: c. 530C > A (p.P178H); exon 6: c. 670G > T (p.E224Stop) 3 years, DOD
18 Male/99 T3N0M0B0 Mutated: exon 8: c.818G > A (p.R273H) 2 years, DOC
19 Male/66 T3N2M0B0 Mutated: exon 5: c.457C > T (p.P153S); exon 5: c.461G > A (p.G154D) 5 years, DOD
AWD, alive with disease; DOD, dead of disease; DOC, dead of other causes.
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frequency and potential role of TP53 mutations in MF according 
to disease stage and course. We have developed a method, which 
enables TP53 sequencing from paraffin-embedded samples from 
a relatively large number of patient samples.
MaTerials anD MeThODs
Materials
In this retrospective study, we reviewed clinical data and histo-
pathology of 157 patients diagnosed with MF in Denmark from 
1980 to 2013 and registered in the Danish pathology registry 
database (Patobank) and The Danish Cutaneous Lymphoma 
Database.1 The diagnosis was made by correlation between clini-
cal findings and histological examination of skin biopsies (17). 
Staging was performed according to ISCL/EORTC criteria (18). 
Also, 30 patients had MF stage IIB or higher, and tissue for p53 
analysis was available in 19 cases (Table  1). Control materials 
included CTCL cell lines SeAx, MyLa200, and MF1885, together 
with biopsies from solid tumors with known p53 mutations (19).
TP53 sequencing
Genomic DNA was extracted from 4  μm  ×  5  μm paraffin-
embedded biopsies from lesional skin and purified using 
the DNA Sample Preparation Kit (Roche Life Science, Basel, 
Switzerland) according to the manufacturer’s instructions. 
Concentration and purity was measured on a Nanodrop 2000 
instrument. PCR amplification of TP53 exon 4–10 is performed 
in five separate nested PCR reactions according to Table 2. The 
primers are designed using Primer 3 software (20, 21) and 
1 www.cldbase.com. 
purchased from MWG Eurofins.2 The nest 1 reactions con-
tained, in a volume of 15 μl, 0.33 μmol/l of each nest 1 primer, 
7.5 μl RedEx PCR master mix (Sigma-Aldrich, St Louis, MO, 
USA) and 50–100 ng genomic DNA and was amplified using 
the following PCR conditions: initial denaturating at 95°C for 
5 min, 25 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s, 
and a final extension at 72°C for 10 min. The nest 2 reactions 
contained, in a volume of 50 μl, 0.4 μM of each nest 2 primer, 
25 μl RedEx PCR master mix (Sigma-Aldrich) and 1 μl 100-fold 
diluted nest 1 product. The nest 2 PCR conditions were the 
same as for the nest 1 reactions except that a total of 35 cycles 
were used. All five nest 1 and nest 2 reactions uses the same 
amplification settings. The PCR products were purified using 
the QIAquick PCR purification kit (Qiagen, Hilden, Germany). 
Sequence reactions were carried out using T3 and T7 prim-
ers, 25 ng purified PCR products, and BigDye Terminator 3.1 
Cycle Sequencing Kit chemistry (Life Technologies, Carlsbad, 
CA, USA) for BigDye incorporation and were subsequently 
sequenced on an ABI3500DX DNA sequenator according to 
the manufacturer’s instructions.
statistical analysis
The overall survival (time in years from the diagnosis to death 
of any cause or to the last observation) was calculated for all 
30 patients with stage >IIB MF. Cox logistic regression was 
performed using SPSS statistical package (version 22, IBM 
Corporation, Armonk, North Castle, NY, USA) using enter, for-
ward, or backward methods. Kaplan–Meier plot was generated in 
SPSS to compare survival curves between patients with mutated 
and germline P53. p ≤ 0.05 was considered significant.
2 www.eurofinsgenomics.eu. 
FigUre 1 | comparison of survival in MF patients with normal TP53 
(solid line) and mutated gene (broken line). Six patients with mutated 
TP53 (Table 1) are compared against the control group of 30 patients with 
stage IIB MF or higher. The difference in survival is significant (p = 0.05) after 
adjustment for stage, age, and gender by Cox logistic regression.  
x-axis – years, y-axis – probability of survival.
TaBle 2 | Primer sequences for sequencing of TP53 exon 4–10.
exon Primer sequence Fragment (bp)
4 F-N1 5′-CCATGGGACTGACTTTCTGC 534
R-N1 5′-GAGGAATCCCAAAGTTCCAA
F-N2 5′-CTGGTAAGGACAAGGGTTGG 457
R-N2 5′-AGAAATGCAGGGGGATACG
5 + 6 F-N1 5′-GGAGGTGCTTACGCATGTTT 588
R-N1 5′-GGGAGGTCAAATAAGCAGCA
F-N2 5′-GCCGTCTTCCAGTTGCTTTA 506
R-N2 5′-GCCACTGACAACCACCCTTA
7 F-N1 5′-CCTGCTTGCCACAGGTCT 294
R-N1 5′-TGATGAGAGGTGGATGGGTAG
F-N2 5′-TGCTTGCCACAGGTCTCC 236
R-N2 5′-GGTCAGAGGCAAGCAGAGG
8 + 9 F-N1 5′-GGGAGTAGATGGAGCCTGGT 486
R-N1 5′-CCCCAATTGCAGGTAAAACA
F-N2 5′-GGGACAGGTAGGACCTGATTT 431
R-N2 5′-AAGAAAACGGCATTTTGAGTG
10 F-N1 5′-TGCATGTTGCTTTTGTACCG 300
R-N1 5′-GAAGGCAGGATGAGAATGGA
F-N2 5′-TGCATGTTGCTTTTGTACCG 263
R-N2 5′-CCTAGGAAGGCAGGGGAGTA
The nest 2 primers contain T3 and T7 tags on F-N2 and R-N2, respectively.
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resUlTs
In 6 out of 19 cases (31%), 1 or several mutations could be 
identified, exhibiting a heterogeneous pattern with mutations in 
different exons at various codon sites (Table 1).
To investigate whether TP53 mutations had impact on sur-
vival, we compared patients with mutated and normal TP53 by 
Kaplan–Meier analysis. Because the sample size was small, we 
decided to compare survival of the 6 patients with mutated p53 
to all 30 patients with stage >IIB MF treated in our center in 
the same time frame (14 women, 16 men; mean age 71.8 years, 
SD 12.6). As shown in Figure 1, patients with mutated TP53 had 
a shorter survival than the controls. The statistically significant 
difference (p = 0.05) was maintained when data were adjusted to 
age, stage, and gender by Cox logistic regression. Adjusted odds 
ratio for death in the presence of mutated P53 was 2.99 (95% 
confidence interval 1.12–8.00, Cox regression) comparing to the 
control group.
DiscUssiOn
The protocol developed in this study allowed for PCR amplifica-
tion and Sanger sequencing of TP53 in archival formalin-fixed 
and paraffin-embedded samples of MF. Only in 4 out of 19 
samples, we were unable to amplify one or several exons, which 
is most probably due to sample age and DNA crosslinking.
The frequency of mutations in stage IIB or higher was 31%, 
which is similar to what has been reported previously (11, 16). 
In contrast, no mutations have been identified in a recent study 
of McGirt et al. (14) who reported Pro72Arg polymorphism to 
be more common in MF. Mutation analysis did not reveal any 
distinctive pattern of alterations in TP53. None of the earlier 
reported mutations were identical to our findings, and our cases 
harbored only one of the known hotspot mutations (R273H 
in case 18). In a recent study, Choi et al. reported 7 different 
mutations located at different sites in 7 out of 40 analyzed 
patients, including the well-known R273H hotspot (22). Our 
cases revealed mainly missense single nucleotide mutations 
resulting in stop codons (cases 1 and 17). Frequent C  >  T 
transitions seem to support the hypothesis that TP53 mutations 
demonstrate an UV B signature, which might be related to the 
effect of phototherapy given repeatedly in the earlier stages of 
the disease (11, 14, 16).
TP53 mutations seem to be associated with worse outcome 
(higher overall mortality). However, this analysis should be inter-
preted with caution since our sample is small, and the presence 
of mutations may reflect more intensive use of phototherapy in 
patients with aggressive, difficult to control disease. Larger sample 
and careful matching with the control patients with normal TP53 
status will be required to elucidate this issue.
aUThOr cOnTriBUTiOns
Design of the study: RG, LG, and LM; data collection: LM, ER, 
LG, and RG; analysis of data and full access to raw data: RG, LG, 
and LM; drafting of the manuscript: GW, LM, LG, and RG; and 
revision of manuscript for important intellectual content: RG, 
LG, LM, GW, and ER.
FUnDing
This study was funded from the operational grant from Bispebjerg 
Hospital and research grant from Aage Bangs Foundation, 
Copenhagen, Denmark.
4Wooler et al. p53 in Cutaneous Lymphoma
Frontiers in Medicine | www.frontiersin.org November 2016 | Volume 3 | Article 51
reFerences
1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. 
Survival outcomes and prognostic factors in mycosis fungoides/Sezary 
syndrome: validation of the revised International Society for Cutaneous 
Lymphomas/European Organisation for Research and Treatment of 
Cancer staging proposal. J Clin Oncol (2010) 28(31):4730–9. doi:10.1200/
JCO.2009.27.7665 
2. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, 
et al. Cutaneous Lymphoma International Consortium Study of outcome in 
advanced stages of Mycosis Fungoides and Sezary Syndrome: effect of specific 
prognostic markers on survival and development of a prognostic model. J Clin 
Oncol (2015) 33(32):3766–73. doi:10.1200/JCO.2015.61.7142 
3. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor 
gene: important milestones at the various steps of tumorigenesis. Genes 
Cancer (2011) 2(4):466–74. doi:10.1177/1947601911408889 
4. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, 
et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. 
Leukemia (2015) 29(2):329–36. doi:10.1038/leu.2014.196 
5. Guieze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, et al. Presence 
of multiple recurrent mutations confers poor trial outcome of relapsed/
refractory CLL. Blood (2015) 126(18):2110–7. doi:10.1182/blood-2015-05- 
647578 
6. Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, et al. 
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in 
chronic lymphocytic leukemia. Leukemia (2015) 29(4):877–85. doi:10.1038/
leu.2014.297 
7. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R, et al. 
Clinical impact of small TP53 mutated subclones in chronic lymphocytic 
leukemia. Blood (2014) 123(14):2139–47. doi:10.1182/blood-2013-11-539726 
8. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos 
CE, et  al. Dysfunction of the TP53 tumor suppressor gene in lymphoid 
malignancies. Blood (2012) 119(16):3668–83. doi:10.1182/blood-2011-11- 
366062 
9. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu W-M, et al. Mutational 
profile and prognostic significance of TP53 in diffuse large B-cell lymphoma 
patients treated with R-CHOP: report from an International DLBCL 
Rituximab-CHOP Consortium Program Study. Blood (2012) 120(19):3986–96. 
doi:10.1182/blood-2012-05-433334 
10. Woollard WJ, Pullabhatla V, Lorenc A, Patel VM, Butler RM, Bayega A, 
et  al. Candidate driver genes in Sezary syndrome: frequent perturbations 
of genes involved in genome maintenance and DNA repair. Blood (2016) 
127(26):3387–97. doi:10.1182/blood-2016-02-699843 
11. McGregor JM, Crook T, Fraser-Andrews EA, Rozycka M, Crossland S, 
Brooks L, et al. Spectrum of p53 gene mutations suggests a possible role for 
ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. 
J Invest Dermatol (1999) 112(3):317–21. doi:10.1046/j.1523-1747.1999.00507.x 
12. Kapur S, Menke MA, Tiemann M, Schubert C, Parwaresch R. Early mycosis 
fungoides: molecular analysis for its diagnosis and the absence of p53 gene 
mutations in cases with progression. J Dermatol Sci (2001) 26(1):36–45. 
doi:10.1016/S0923-1811(00)00159-6 
13. Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but 
no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for 
the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 
(2002) 118(6):949–56. doi:10.1046/j.1523-1747.2002.01794.x 
14. McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, et al. 
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoi-
des. Blood (2015) 126(4):508–19. doi:10.1182/blood-2014-11-611194 
15. Li G, Chooback L, Wolfe JT, Rook AH, Felix CA, Lessin SR, et  al. 
Overexpression of p53 protein in cutaneous T cell lymphoma: relationship 
to large cell transformation and disease progression. J Invest Dermatol (1998) 
110(5):767–70. doi:10.1046/j.1523-1747.1998.00167.x 
16. Whittaker S. Molecular genetics of cutaneous lymphomas. Ann N Y Acad Sci 
(2001) 941:39–45. doi:10.1111/j.1749-6632.2001.tb03709.x 
17. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, 
et  al. Defining early mycosis fungoides. J Am Acad Dermatol (2005) 
53(6):1053–63. doi:10.1016/j.jaad.2005.08.057 
18. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. 
Revisions to the staging and classification of mycosis fungoides and Sezary 
syndrome: a proposal of the International Society for Cutaneous Lymphomas 
(ISCL) and the cutaneous lymphoma task force of the European Organization 
of Research and Treatment of Ca. Blood (2007) 110(6):1713–22. doi:10.1182/
blood-2007-03-055749 
19. Manfe V, Biskup E, Johansen P, Kamstrup MR, Krejsgaard TF, Morling N, et al. 
MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous 
T-cell lymphoma: role of p53. J Invest Dermatol (2012) 132(5):1487–96. 
doi:10.1038/jid.2012.10 
20. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, 
et  al. Primer3 – new capabilities and interfaces. Nucleic Acids Res (2012) 
40(15):e115. doi:10.1093/nar/gks596 
21. Koressaar T, Remm M. Enhancements and modifications of primer design 
program Primer3. Bioinformatics (2007) 23(10):1289–91. doi:10.1093/
bioinformatics/btm091 
22. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et  al. Genomic 
landscape of cutaneous T cell lymphoma. Nat Genet (2015) 47(9):1011–9. 
doi:10.1038/ng.3356 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer [UK] and handling Editor declared their shared affiliation, and the 
handling Editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Wooler, Melchior, Ralfkiaer, Rahbek Gjerdrum and Gniadecki. 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
